It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
An understanding of factors influencing implementation is essential to realise the benefits of population-based reproductive genetic carrier screening programs. The aim of this study was to synthesise data collected during the Australian Reproductive Genetic Carrier Screening Project (Mackenzie’s Mission) to track how priorities shifted over time and identify important factors during scaling-up and for sustainment. We used a multi-method qualitative approach to integrate longitudinal project data collected from 10 project committees with 16 semi-structured interviews conducted with study team members. Both datasets were analysed using the Consolidated Framework for Implementation Research (CFIR) to identify constructs of interest within early, mid-point, and future implementation phases. Several CFIR constructs were present across implementation. The complexity of implementation presented challenges that were overcome through a quality-designed and packaged product, formal and informal networks and communication, and access to knowledge and information. Addressing the diverse consumer needs through resources and increasing community and non-genetic speciality engagement remained a priority throughout and for future sustainment. Going forward, further addressing program complexities and securing funding were emphasised. By applying an implementation framework, findings from this study may be useful for future effort towards building and/or sustaining reproductive genetic carrier screening programs.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Best, Stephanie 2
; Long, Janet C. 3 ; Theodorou, Tahlia 3 ; Pope, Catherine 4 ; Hibbert, Peter 5 ; Williams, Sharon 6 ; Freeman, Lucinda 7 ; Righetti, Sarah 8 ; Archibald, Alison D. 9 ; Braithwaite, Jeffrey 10 1 Macquarie University, Australian Institute of Heath Innovation, Sydney, Australia (GRID:grid.1004.5) (ISNI:0000 0001 2158 5405); Australian Genomics Health Alliance, Melbourne, Australia (GRID:grid.1004.5); Murdoch Children’s Research Institute, Melbourne, Australia (GRID:grid.1058.c) (ISNI:0000 0000 9442 535X)
2 Macquarie University, Australian Institute of Heath Innovation, Sydney, Australia (GRID:grid.1004.5) (ISNI:0000 0001 2158 5405); Australian Genomics Health Alliance, Melbourne, Australia (GRID:grid.1004.5); Murdoch Children’s Research Institute, Melbourne, Australia (GRID:grid.1058.c) (ISNI:0000 0000 9442 535X); Peter MacCallum Cancer Centre, Department of Health Services Research, Melbourne, Australia (GRID:grid.1055.1) (ISNI:0000000403978434); Victorian Comprehensive Cancer Centre, Melbourne, Australia (GRID:grid.431578.c) (ISNI:0000 0004 5939 3689); University of Melbourne, Sir Peter MacCallum Cancer Centre Dept of Oncology, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
3 Macquarie University, Australian Institute of Heath Innovation, Sydney, Australia (GRID:grid.1004.5) (ISNI:0000 0001 2158 5405)
4 University of Oxford, Nuffield Department of Primary Care Health Sciences, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948)
5 Macquarie University, Australian Institute of Heath Innovation, Sydney, Australia (GRID:grid.1004.5) (ISNI:0000 0001 2158 5405); University of South Australia, IIMPACT in Health, Allied Health and Human Performance, Adelaide, Australia (GRID:grid.1026.5) (ISNI:0000 0000 8994 5086)
6 Swansea University, School of Health & Social Care, Swansea, UK (GRID:grid.4827.9) (ISNI:0000 0001 0658 8800)
7 University of New South Wales, School of Women’s and Children’s Health, Sydney, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432); University of Technology Sydney, Graduate School of Health, Sydney, Australia (GRID:grid.117476.2) (ISNI:0000 0004 1936 7611)
8 University of New South Wales, School of Women’s and Children’s Health, Sydney, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432); Sydney Children’s Hospital Network, Centre for Clinical Genetics, Sydney, Australia (GRID:grid.430417.5) (ISNI:0000 0004 0640 6474)
9 Murdoch Children’s Research Institute, Victorian Clinical Genetics Services, Melbourne, Australia (GRID:grid.1058.c) (ISNI:0000 0000 9442 535X); The University of Melbourne, Department of Paediatrics, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
10 Macquarie University, Australian Institute of Heath Innovation, Sydney, Australia (GRID:grid.1004.5) (ISNI:0000 0001 2158 5405); Australian Genomics Health Alliance, Melbourne, Australia (GRID:grid.1004.5)




